Vedolizumab vs adalimumab in patients with active ulcerative colitis
Best Practice Nordic | Mar 2019 | | ECCO
In this MEDtalk professor Stefan Schreiber present a head-to-head study of the efficacy and safety of vedolizumab and adalimumab for treatment over 52 weeks in adults with moderately to severely active ulcerative colitis (UC). The first study to directly compare two biological agents in IBD. Click and hear the results.